The Evolving Landscape of Cutaneous Sarcoidosis: Pathogenic Insight, Clinical Challenges, and New Frontiers in Therapy
Abstract Sarcoidosis is a multisystem disorder of unknown etiology characterized by accumulation of granulomas in affected tissue. Cutaneous manifestations are among the most common extrapulmonary manifestations in sarcoidosis and can lead to disfiguring disease requiring chronic therapy. In many patients, skin disease may be the first recognized manifestation of sarcoidosis, necessitating a thorough evaluation for systemic involvement. Although the precise etiology of sarcoidosis and the pathogenic mechanisms leading to granuloma formation, persistence, or resolution remain unclear, recent research has led to significant advances in our understanding of this disease. This article reviews recent advances in epidemiology, sarcoidosis clinical assessment with a focus on the dermatologist’s role, disease pathogenesis, and new therapies in use and under investigation for cutaneous and systemic sarcoidosis..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
American journal of clinical dermatology - 23(2022), 4 vom: 18. Mai, Seite 499-514 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wu, Julie H. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022 |
|---|
| doi: |
10.1007/s40257-022-00693-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR047708972 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR047708972 | ||
| 003 | DE-627 | ||
| 005 | 20230519232340.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220729s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40257-022-00693-0 |2 doi | |
| 035 | |a (DE-627)SPR047708972 | ||
| 035 | |a (SPR)s40257-022-00693-0-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wu, Julie H. |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Evolving Landscape of Cutaneous Sarcoidosis: Pathogenic Insight, Clinical Challenges, and New Frontiers in Therapy |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022 | ||
| 520 | |a Abstract Sarcoidosis is a multisystem disorder of unknown etiology characterized by accumulation of granulomas in affected tissue. Cutaneous manifestations are among the most common extrapulmonary manifestations in sarcoidosis and can lead to disfiguring disease requiring chronic therapy. In many patients, skin disease may be the first recognized manifestation of sarcoidosis, necessitating a thorough evaluation for systemic involvement. Although the precise etiology of sarcoidosis and the pathogenic mechanisms leading to granuloma formation, persistence, or resolution remain unclear, recent research has led to significant advances in our understanding of this disease. This article reviews recent advances in epidemiology, sarcoidosis clinical assessment with a focus on the dermatologist’s role, disease pathogenesis, and new therapies in use and under investigation for cutaneous and systemic sarcoidosis. | ||
| 700 | 1 | |a Imadojemu, Sotonye |4 aut | |
| 700 | 1 | |a Caplan, Avrom S. |0 (orcid)0000-0003-3864-9174 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of clinical dermatology |d Berlin [u.a.] : Springer, 2000 |g 23(2022), 4 vom: 18. Mai, Seite 499-514 |w (DE-627)SPR032954131 |w (DE-600)2043675-0 |x 1179-1888 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2022 |g number:4 |g day:18 |g month:05 |g pages:499-514 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40257-022-00693-0 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2022 |e 4 |b 18 |c 05 |h 499-514 | ||